MTI’s 2025 cohort expands with 8 startups in Heart and Brain Health accelerator: what’s next?

MTI, recognized as the worlds largest and most impactful accelerator for medical technology startups, has expanded its 2025 cohort to include eight startups in the Heart and Brain Health Accelerator. This specialized track is conducted in collaboration with the American Heart Association Ventures and the Center for Health Technology and Innovation (CHTI).

The 2025 cohort comprises 65 companies, selected from nearly 1,500 global applicants, representing the top four percent. These startups will engage in MTIs flagship four-month program, which aims to de-risk innovation and accelerate the path to U.S. market success.

"MTI alumni have collectively brought over 400 products to market and raised $10 billion in follow-on funding," underscoring the programs impact.

Participants in this years cohort will compete for a share of $800,000 in non-dilutive funding, with winners determined by audience votes at major industry conferences. The program also includes a Plastic Surgery Accelerator track in partnership with the American Society for Plastic Surgeons (ASPS), featuring five companies.

The Heart and Brain Health Accelerator track focuses on innovations targeting cardiovascular and neurological health, reflecting growing industry emphasis on these critical areas. By collaborating with leading organizations like the American Heart Association Ventures and CHTI, MTI aims to provide startups with strategic resources and networks to enhance their development and commercialization efforts.

This expansion highlights MTIs commitment to fostering cutting-edge medical technologies that address significant health challenges, accelerating their journey from concept to market-ready solutions.

MTI’s 2025 accelerator cohort includes eight startups in its Heart and Brain Health track, partnering with the American Heart Association Ventures and CHTI. The program, selecting 65 companies from 1,500 applicants, offers $800,000 in non-dilutive funding to accelerate medical technology innovations toward U.S. market success.